Keyphrases
High-risk Human Papillomavirus (HR-HPV)
100%
HPV16
51%
Human Papillomavirus Vaccine
40%
Vaccine Effectiveness
33%
Quality of Life
33%
Population-based
33%
Cluster Randomized Trial
33%
Cancer Population
33%
Cervical Cancer Screening
32%
Vaccination
18%
Cancer Cases
14%
Cervical Cancer
14%
Role Functioning
13%
RAND-36
13%
EQ-VAS
13%
Human Papillomavirus Types
12%
Birth Cohort
11%
Trial Registration
10%
Invasive Cancer
7%
Tongue Cancer
7%
Vulvar Cancer
7%
HPV 52
7%
Vaginal Cancer
7%
Adverse Effects
6%
Emotional Well-being
6%
Disease Burden
6%
Screening Program
6%
No Significant Difference
6%
Social Functioning
6%
Program Planning
6%
VAS Score
6%
Screening Frequency
6%
Well-being Domains
6%
Quality of Life Questionnaire
6%
Emotional Role
6%
General Health
6%
Screening Protocol
6%
Cervical Lesions
6%
Pap Cytology
6%
Genital Warts
6%
Safety Concerns
5%
Trial Participants
5%
Cervical Cancer Incidence
5%
ASC-H
5%
Cytological Findings
5%
Screening Age
5%
Vaccine Trial
5%
Loss of Life
5%
Randomized Trial
5%
Medicine and Dentistry
Wart Virus
66%
Malignant Neoplasm
33%
Vaccine
33%
Cluster Randomized Trial
33%
Quality of Life
33%
Cervical Cancer Screening
22%
Arm
16%
Human Papillomavirus Type 16
13%
Cervical Cancer
10%
Genital Wart
5%
Program Planning
5%
Social Interaction
5%
Screening
5%
Cytotechnology
5%
Adverse Event
5%
Disease Burden
5%
Human Papillomavirus Related Disease
5%
Emotional Well-Being
5%
Tumor Invasion
5%
Human Papillomavirus Type 52
5%
Tongue Cancer
5%
Vagina Cancer
5%
Immunology and Microbiology
Wart Virus
66%
Arm
53%
Cancer Screening
29%
Human Papillomavirus Type 16
24%
Prevalence
9%
Genital Wart
6%
Wellbeing
6%
Disease Burden
6%
Screening
6%
Human Papillomavirus Related Disease
6%
